行情

AXSM

AXSM

Axsome
NASDAQ

实时行情|Nasdaq Last Sale

85.20
-2.56
-2.92%
盘后: 85.49 +0.29 +0.34% 16:34 01/24 EST
开盘
87.78
昨收
87.76
最高
88.25
最低
84.30
成交量
53.10万
成交额
--
52周最高
109.94
52周最低
7.63
市值
31.35亿
市盈率(TTM)
-53.0676
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AXSM 新闻

  • 微博2020让红包飞集卡玩出新高度 超14亿人次参与
  • 新浪科技.1小时前
  • 玩游戏了解流行病?单机游戏“瘟疫公司”多国畅销
  • 新京报网.2小时前
  • 携程升级重大灾害保障金至2亿
  • 36氪.3小时前
  • 新东方向湖北省红十字会捐款2000万元
  • 新浪科技.5小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

AXSM 简况

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
展开

Webull提供Axsome Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。